Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer | Zendy

AI Assistant Blog Pricing

Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.